

# Yusuke Moritoh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/120934/publications.pdf>

Version: 2024-02-01

13  
papers

255  
citations

933447  
10  
h-index

1125743  
13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

303  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice. Scientific Reports, 2016, 6, 32072.	3.3	58
2	The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals. Nature Communications, 2021, 12, 4847.	12.8	41
3	SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 172-181.	2.5	32
4	Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety. Journal of Medicinal Chemistry, 2020, 63, 10352-10379.	6.4	21
5	The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 21-27.	2.5	18
6	SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice. Diabetes, Obesity and Metabolism, 2019, 21, 2228-2239.	4.4	16
7	Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice. Pharmacological Research, 2021, 163, 105337.	7.1	16
8	SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes, 2021, 70, 2364-2376.	0.6	14
9	Discovery and characterization of a small molecule enteropeptidase inhibitor, SCO-792. Pharmacology Research and Perspectives, 2019, 7, e00517.	2.4	13
10	GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve. PLoS ONE, 2019, 14, e0222653.	2.5	11
11	Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease. Diabetes, Obesity and Metabolism, 2021, 23, 86-96.	4.4	8
12	Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 631-640.	0.7	5
13	Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Molecular Pharmacology, 2021, 99, 286-293.	2.3	2